News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals
(NQ:
IONS
)
39.19
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ionis Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
Next >
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
October 18, 2024
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.
Via
Investor's Business Daily
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (13 Ratings)
September 26, 2024
Via
Benzinga
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
September 10, 2024
Via
Benzinga
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
September 10, 2024
Via
Benzinga
What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals
August 26, 2024
Via
Benzinga
12 Analysts Have This To Say About Ionis Pharmaceuticals
August 02, 2024
Via
Benzinga
The Latest Analyst Ratings For Ionis Pharmaceuticals
July 16, 2024
Via
Benzinga
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
June 27, 2024
Via
Benzinga
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
July 22, 2024
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety...
Via
Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
July 22, 2024
Biogen previously decided against opting into Ionis' Angelman program.
Via
Investor's Business Daily
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
June 24, 2024
Via
Benzinga
Masters In Trading - Saturday, June 22
June 22, 2024
In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio.
Via
Talk Markets
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
June 03, 2024
Via
Benzinga
The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals
May 08, 2024
Via
Benzinga
The Latest Analyst Ratings For Ionis Pharmaceuticals
April 09, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals
February 22, 2024
Via
Benzinga
Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
May 31, 2024
Discover the results of Ionis Pharmaceuticals' Phase 3 studies on donidalorsen for hereditary angioedema. FDA application submission expected this year.
Via
Benzinga
Exposures
Product Safety
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
May 31, 2024
The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS.
Via
Benzinga
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
May 16, 2024
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes.
Via
Benzinga
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
May 09, 2024
Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks.
Via
InvestorPlace
IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
May 07, 2024
IONS stock results show that Ionis Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Earnings Scheduled For February 21, 2024
February 21, 2024
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.
Via
Benzinga
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts
January 18, 2024
Via
Benzinga
Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows
March 13, 2024
Ionis Pharmaceuticals reports positive Phase 2 results for ION224, showing significant improvement in MASH and liver histology without worsening fibrosis. Safe and well-tolerated treatment with...
Via
Benzinga
JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know
February 01, 2024
Via
Benzinga
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
January 31, 2024
Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval.
Via
Benzinga
Exposures
Product Safety
Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study
January 22, 2024
Phase 3 OASIS-HAE study results by Ionis Pharmaceuticals Donidalorsen shows remarkable efficacy, safety, and plans for FDA submission.
Via
Benzinga
Exposures
Product Safety
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
January 04, 2024
A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,...
Via
Benzinga
Topics
ETFs
10 Health Care Stocks Whale Activity In Today's Session
January 02, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.